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Background: The recently discovered small-molecule BI-2 potently blocks HIV-1 infection. BI-2 binds to the N-terminal
domain of HIV-1 capsid. BI-2 utilizes the same capsid pocket used by the small molecule PF74. Although both drugs bind
to the same pocket, it has been proposed that BI-2 uses a different mechanism to block HIV-1 infection when compared
to PF74.
Findings: This work demonstrates that BI-2 destabilizes the HIV-1 core during infection, and prevents the binding of the
cellular factor CPSF6 to the HIV-1 core.
Conclusions: Overall this short-form paper suggests that BI-2 is using a similar mechanism to the one used by PF74 to
block HIV-1 infection.
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The ability of the novel HIV-1 inhibitor BI-2 to po-
tently block HIV-1 infection has been correlated with
stabilization of in vitro assembled HIV-1 CA-NC com-
plexes [1-3]. Crystal structure of the drug with the
N-terminal domain of capsid (CANTD) revealed that BI-2
binds in the site 2 pocket [1], as it has been shown for
the small-molecule inhibitor PF74 [1,4,5]. Using a novel
capsid stability assay, we have demonstrated that BI-2
and PF74 stabilize in vitro assembled HIV-1 capsid-
nucleocapsid (CA-NC) complexes [2]. Counter intui-
tively, PF74 destabilizes the HIV-1 core during infection
of cells [5]. In addition, several reports have demon-
strated that PF74 prevents the binding of the cellular
factor cleavage and polyadenylation specific factor 6
(CPSF6) to the viral capsid [2,6]. Previous observations
have shown that BI-2 stabilizes in vitro assembled HIV-1
CA-NC complexes by using two different assays [1,2].
Because BI-2 has been suggested to inhibit HIV-1 infec-
tion, at least in part, by stabilizing the viral capsid
[1,2], we investigated the effects of BI-2 in infection
by analyzing 1) HIV-1 DNA metabolism, 2) the fate of* Correspondence: felipe.diaz-griffero@einstein.yu.edu
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unless otherwise stated.the HIV-1 capsid, 3) binding of CPSF6 to HIV-1 capsid,
and 4) the ability of BI-2 to block infection by other
retroviruses.
BI-2 blocks infection of HIV-1 after reverse transcription
but prior to nuclear import
We initially studied the ability of BI-2 to block HIV-1-
GFP infection in canine Cf2Th cells at the indicated
concentrations (Figure 1A). As a control, we performed
similar experiments using the small-molecule PF74
[1,2,4,5]. Our experiments showed that 50 μM of BI-2 is
equivalent to 5 μM of PF74 when comparing inhibition
of HIV-1-GFP infection (Figure 1A). These drugs did not
exhibit cellular toxicity at the used concentrations, as de-
termined by propidium iodide exclusion [7]. Next we
challenged dog Cf2Th cells with similar amounts of HIV-
1-GFP in the presence of BI-2. Infections were harvested
at 7, 24 and 48 hours post-infection to analyze late
reverse transcripts (LRT) (B), formation of 2-LTR cir-
cles (C) and infectivity (D), respectively. As a control, we
performed similar infections in the presence of DMSO.
To control for a block in reverse transcription, we used
the inhibitor nevirapine [8], which completely blocks HIV-
1-GFP reverse transcription (Figure 1B). BI-2 did not
affect the occurrence of reverse transcription when com-
pared to the effect of nevirapine (Figure 1B); this result is
reminiscent of the effect of the related small moleculetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 BI-2 blocks the formation of 2-LTR circles during HIV-1 infection. Cf2Th cells were challenged with HIV-1 expressing GFP as a
reporter (HIV-1-GFP) in the presence of increasing concentrations of BI-2 or PF74. Infection was determined 48 hours post-infection by measuring
the percentage of GFP-positive cells by flow cytometry (A). Similar results were obtained in three independent experiments and a representative
experiment is shown. Similarly, Cf2Th cells treated with BI-2, PF74 or DMSO were challenged with DNAse-pretreated HIV-1-GFP viruses. Subsequently,
cells were harvested 7, 24 and 48 hours post-infection to measure HIV-1 late reverse transcripts (LRT) (B), formation of HIV-1 2-LTR circles (C) and
infectivity (D), respectively. As control, we performed similar measurements in the presence of the reverse transcriptase inhibitor nevirapine (Nev)
(B-D). Similar results were obtained in three independent experiments and standard deviations are shown. (E) Similarly, Cf2Th cells treated with
the indicated concentrations of BI-2 were challenged with DNAse-pretreated HIV-1-GFP viruses. Subsequently, cells were harvested 7 and 48 hours
post-infection to measure HIV-1 LRT (left panel) and infection (right panel), respectively. As a control, we performed similar experiments in the
presence of the reverse transcriptase inhibitor nevirapine (Nev). Similar results were obtained in three independent experiments and standard
deviations are shown. (F) Formation of Late reverse transcripts by HIV-1-GFP and HIV-1-T107N-GFP were measured at 7, 24 and 48 hours
post-infection in the presence of the indicated amounts of BI-2 or PF-74. Viral Infection was determined by counting the percentage of GFP-positive
cells 48 hours post-infection. Similar results were obtained in three independent experiments and standard deviations are shown.
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blocked the formation of 2-LTR circles (Figure 1C).
These results indicated that BI-2 blocks HIV-1-GFP in-
fection after reverse transcription but prior to nuclear
import, as demonstrated for BI-1 [1]. PF74 had a greater
effect on the occurrence of reverse transcription when
compared to BI-2, and potently blocked the formation of
2-LTR circles (Figure 1B-C), as previously shown [4,5].
Inhibition of HIV-1-GFP infection by BI-2 was compar-
able to PF74 at the indicated concentrations (Figure 1D).
Previous observations showed that BI-1, a similar mol-
ecule to BI-2, did not affected the occurrence of reverse
transcription [1]. Next we measured occurrence of HIV-1
reverse transcription in the presence of different concen-
trations of BI-2. To this end, we challenged dog Cf2Th
cells with similar amounts of HIV-1-GFP in the presence
of the indicated concentrations of BI-2, and measured
the occurrence of reverse transcription and infection at 7
and 48 hours post-infection, respectively (Figure 1E). In
agreement with previous findings using BI-1 [1], these
experiments showed that BI-2 does not affect the occur-
rence of reverse transcription. As a control, we per-
formed similar infections in the presence of nevirapine
(Figure 1E), an inhibitor of reverse transcription. In
addition, we monitored HIV-1 and HIV-1-T107N LRTsFigure 2 BI-2 destabilizes the HIV-1 Core during infection. (A) Cf2Th c
and used to perform the fate of the capsid assay 12 hours post-infection, a
post-nuclear supernatants that were layered onto a 50% sucrose cushion to
PELLET fractions were analyzed by Western blotting using antibodies again
the presence of PF74. The percentages of pelletable capsids relative to the
were obtained in three independent experiments and standard deviations
bearing the capsid change T107N in the presence of BI-2, and used to perf
we performed experiments in cells stably expressing rhesus TRIM5α.The pe
presence of DMSO are shown. Similar results were obtained in three indep
in vitro assembled HIV-1 CA-NC complexes in destabilization buffer containi
were measured as described [2]. Input and Pellet fractions were analyzed
stability of in vitro assembled HIV-1 CA-NC complexes in stabilization buff
experiments. (D) Stability of wild type (upper panel) or T107N mutant (low
buffer containing cell extracts at increasing concentrations of BI-2 was me
independent experiments.at 7, 24, and 48 hours post-infection in the presence of
BI-2 or PF-74 (Figure 1F). Similarly, we found that BI-2
did not affect the formation of HIV-1 LRTs. In addition,
BI-2 did not affect the formation of LRTs by HIV-1-
T107N.
BI-2 destabilizes the HIV-1 core during infection
We investigated the fate of the HIV-1 capsid in the pres-
ence of BI-2. For this purpose, we challenged Cf2Th
cells with HIV-1-GFP in the presence of 50 μM BI-2 and
performed the fate of the capsid 12 hours post-infection,
as previously described [9-11]. As shown in Figure 2A,
the use of BI-2 destabilized the HIV-1 core during infec-
tion when compared with the DMSO control. As a con-
trol, we used 5 μM PF74 that destabilized the HIV-1
core (Figure 2A), as previously shown [5]. Our results
suggested that BI-2, like PF74, destabilizes the HIV-1
core during infection. To show that the destabilization
of the HIV-1 core observed in the presence of BI-2 is
specific to capsid, we performed the fate of the capsid
assay using an HIV-1-GFP virus bearing the mutation
T107N, which confers HIV-1 resistance to BI-2 and
PF74 [1,4]. As shown in Figure 2B, BI-2 and PF74 did
not affect the stability of the HIV-1 core bearing the
change T107N. These results suggested that the abilityells were challenged with HIV-1-GFP viruses in the presence of BI-2,
s described [9,11]. Briefly, HIV-1 infected cells were used to prepare
separate soluble from pelletable HIV-1 capsids. INPUT, SOLUBLE and
st HIV-1 CA p24. As control, we studied the fate of the HIV-1 capsid in
infected control in the presence of DMSO are shown. Similar results
are shown. (B) Cf2Th cells were challenged with HIV-1-GFP viruses
orm the fate of the capsid assay 12 hours post-infection. As a control,
rcentages of pelletable capsids relative to the infected control in the
endent experiments and standard deviations are shown. (C) Stability of
ng increasing concentrations of BI-2 (upper panel) or PF74 (lower panel)
by Western blotting using antibodies against HIV-1 CA p24. As control,
er was measured. Similar results were obtained in three independent
er panel) in vitro assembled HIV-1 CA-NC complexes in stabilization
asured, as described [2]. Similar results were obtained in three
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capsid. As a control, we showed that TRIM5αrh destabi-
lizes the HIV-1 core (Figure 2B), as previously shown
[12,13]. Next, we tested the ability of BI-2 to stabilize
in vitro assembled HIV-1 CA-NC complexes using our
previously published assay [2]. As we have previously
shown, BI-2 as well as PF74 stabilize HIV-1 CA-NC
complexes (Figure 2C) [2]. These results showed thatFigure 3 BI-2 prevents the binding of the cellular factor CPSF6 to HIV
assembled HIV-1 CA-NC complexes in the presence of BI-2 was analyzed as
transfected with a CPSF6-FLAG construct (Input) were incubated with in vit
for 1 h. Subsequently, extracts were applied onto 70% sucrose cushion and
and Pellet fractions were analyzed using anti-FLAG and anti-p24 antibodies
complexes was studied in the presence of PF74. Similar results were obtaine
is shown. To control for the bona fide origin of in vitro assembled SIVmac CA
monkeys tagged with an HA epitope (TRIM5αTamarin-HA) to bind SIVmac caps
complexes in the presence of increasing concentrations of BI-2 was analy
using increasing concentrations of PF74 (right panel). Similar results were
experiments is shown. (C) To show that the interaction of CPSF6 with in
capsid protein, we tested the ability of CPSF6 to bind in vitro assembled
were obtained in three independent experiments and a representative exBI-2, like PF74, stabilizes in vitro assembled HIV-1 CA-
NC complexes, which is in agreement with previous
reports [1,2]. Contrary to in vitro assembled HIV-1 CA-
NC complexes that are mainly composed of capsid
hexamers [14], the HIV-1 core is composed of capsid
pentamers and hexamers [15,16]. The mature fullerene
core is an assembly of capsid subunits displaying mul-
tiple quasi-equivalent conformations, which arise in part-1 CA-NC complexes. (A) The ability of CPSF6 to bind in vitro
previously described [22]. Briefly, extracts of 293 T cells transiently
ro assembled HIV-1 or SIVmac CA-NC complexes in the presence BI-2
centrifuged, and the pelleted fraction was collected (Pellet). Input
. As control, the binding of CPSF6 to in vitro assembled HIV-1 CA-NC
d in three independent experiments and a representative experiments
-NC complexes, we tested the ability of TRIM5α protein from Tamarin
id. (B) The ability of CPSF6 to bind in vitro assembled HIV-1 CA-NC
zed (left panel). As a control, similar experiments were performed
obtained in three independent experiments and a representative
vitro assembled HIV-1 CA-NC complexes is only dependent upon the
HIV-1 CA-NC complexes bearing the change N74D. Similar results
periments is shown.
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domains of capsid. These multiple quasi-equivalent confor-
mations result in the formation of hexamers and penta-
mers, which allow the formation of a curved capsid lattice.
One possibility is that BI-2 and PF-74 limits the flexibility
of the capsid to a range compatible only with the forma-
tion of hexamers; this might be the reason that BI-2 and
PF74 stabilize in vitro assembled HIV-1 CA-NC complexes
but destabilize the HIV-1 core during infection. A second
possibility is that BI-2 requires the presence of cellular fac-
tors in order to destabilize in vitro assembled HIV-1 CA-
NC complexes. To rule out that the ability of BI-2 to
destabilize capsid complexes depends upon the presence of
cellular factors, we tested the ability of BI-2 to destabilize
in vitro assembled HIV-1 CA-NC complexes in the pres-
ence of cellular extracts. As shown in Figure 2D, the pres-
ence of cellular extracts did not alter the ability of BI-2 to
destabilize capsid. As a control, similar experiments were
performed using the capsid mutant T107N, which is resist-
ant to BI-2 (Figure 2D). Future structural studies will shed
light on this discrepancy.
BI-2 prevents the binding of CPSF6 to in vitro assembled
HIV-1 CA-NC complexes
Expression of CPSF6 is required for the HIV-1 infection
phenotype observed in human TNPO3-depleted cellsFigure 4 BI-2 blocks HIV-1 and SIVmac infection. Cf2Th cells were challeng
BI-2. Infection was determined by measuring the percentage of GFP-positive c
similar experiments in the presence of the small-molecule PF74. Similar results
experiment is shown.[17-19]. We and others have previously demonstrated
that the small-molecule HIV-1-inhibitor PF74 prevents
the binding of CPSF6 to HIV-1 capsid [6,17]. Because of
the similar phenotypes observed for HIV-1-GFP infec-
tion when using BI-2 and PF74, we tested the ability
CPSF6 to bind in vitro assembled HIV-1 CA-NC com-
plexes in the presence of BI-2. As shown in Figure 3A,
BI-2 prevents the ability of CPSF6 to bind in vitro assem-
bled HIV-1 CA-NC complexes. As previously shown,
PF74 also prevented the binding of CPSF6 to in vitro as-
sembled HIV-1 CA-NC complexes [17]. Interestingly, BI-
2 and PF74 also inhibited the binding of CPSF6 to in vitro
assembled simian immunodeficiency virus (SIVmac) CA-
NC complexes (Figure 3A). As a control to show the bona
fide origin of the SIVmac capsid, we showed that TRIM5α
from tamarin monkeys binds to in vitro assembled SIVmac
CA-NC complexes (Figure 3A) [20]. These results sug-
gested that BI-2 prevents the binding of CPSF6 to the
HIV-1 and SIVmac cores. Next, we performed a dose re-
sponse curve to better understand the ability of BI-2 to
prevent the binding of CPSF6 to in vitro assembled HIV-1
CA-NC complexes. As shown in Figure 3B, we observed
that using BI-2 at 50 μM completely inhibit the binding of
CPSF6 to in vitro assembled HIV-1 CA-NC complexes.
For comparison, we showed a dose response curve to
understand the ability of PF74 to interfere with theed with increasing amount of the indicated retrovirus in the presence of
ells by flow cytometry 48 hours post infection. As control, we performed
were obtained in three independent experiments and a representative
Fricke et al. Retrovirology 2014, 11:120 Page 6 of 7
http://www.retrovirology.com/content/11/1/120binding of CPSF6 to in vitro assembled HIV-1 CA-NC
complexes. As we have previously shown using PF74 at
5 μM inhibited the ability of CPSF6 to bind in vitro assem-
bled HIV-1 CA-NC complexes [17]. Altogether these re-
sults showed that BI-2 prevents the ability of CPSF6 to
interact with the HIV-1 core. Because CPSF6 binds to nu-
cleic acids, and HIV-1 CA-NC complexes are assembled
in the presence of nucleic acids [21], we performed a con-
trol to demonstrate that the interaction of CPSF6 with
in vitro assembled HIV-1 CA-NC complexes is only
dependent upon the capsid protein. To this end, we tested
the ability of CPSF6 to bind in vitro assembled HIV-1 CA-
NC complexes bearing the change N74D, which confers
HIV-1 resistance to the overexpression of cytosolic CPSF6
[17,18]. As shown in Figure 3C, CPSF6 did not bind to
vitro assembled HIV-1 CA-NC complexes bearing the
change N74D. These results indicated that CPSF6 is spe-
cifically binding to capsid, as shown [17].
Ability of BI-2 to block infection by different retroviruses
Next we explored the ability of BI-2 to block infection
by different retroviruses. For this purpose, we challenged
Cf2Th cells with increasing amounts of different retrovi-
ruses expressing GFP as reporter of infection (Figure 4),
including HIV-1, SIVmac, HIV-2ROD, bovine immunodefi-
ciency virus (BIV), feline immunodeficiency virus (FIV),
equine infectious anemia virus (EIAV), N-tropic murine
leukemia virus (N-MLV), B-tropic murine leukemia virus
(B-MLV) and Moloney murine leukemia virus (Mo-MLV).
Viruses expressing GFP as a reporter were prepared as pre-
viously described [23]. Interestingly, BI-2 potently blocked
HIV-1 and SIVmac but not HIV-2ROD, BIV, FIV, EIAV,
N-MLV, B-MLV and Mo-MLV. As a control, we per-
formed similar infections in the presence of PF74
(Figure 4). As previously shown PF74 blocks HIV-1-GFP
and SIVmac-GFP infection [5,6,17,24]. Interestingly, we
found a parallel between the ability of BI-2 to inhibit infec-
tion by HIV-GFP and SIVmac-GFP with the ability of BI-2
to prevent the binding of CPSF6 with the HIV-1 and
SIVmac cores.
This short-form article thoroughly examined and com-
pared the effects of BI-2 and PF74 on HIV-1 infection.
Our novel findings demonstrate that BI-2, similar to
PF74, destabilizes the HIV-1 core during infection and
prevents the binding of CPSF6 to the HIV-1 core.
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